“Significant psychiatric and gastrointestinal tract adverse effects were observed [ in people given 20 mg of Acomplia ( rimonabant ) ] but were usually mild or moderate in severity,” noted the authors of the STRADIVARIUS study that involved 839 patients at 112 centers in North America, Europe, and Australia.
A total of 43.4 percent of those given Acomplia ( rimonabant ) reported psychiatric side effects versus 28.4 percent of those given a placebo.
“These adverse events consisted primarily of an increase in anxiety and depression,” the authors noted.
© Copyright 2003-2012 - Larry Hobbs - All Rights Reserved.